October 9, 2025Circulation Research

Abstract Wed126: Myosin S2 and cMyBP-C Interactions in Cardiac Contractility and Hypertrophic Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Authors

SRStephanie RzewnickiUniversity of Arizona TSTaejeong SongUniversity of Arizona RSRohit SinghAmgen (United States)

Discussion

Member takes

Implication

Research uncovers how the myosin S2 region mutation alters cMyBP-C interactions, implying potential therapeutic targets in hypertrophic cardiomyopathy.

Key Points

The E930del mutation in β-myosin disrupts its interaction with cMyBP-C, leading to diastolic dysfunction.
Homologous mouse models exhibit cardiac hypertrophy and enhanced contractile function, indicating mutation-specific effects.
Identifying the myopeptide Amg 27119 offers a new strategy for improving cardiac contractility in hypertrophic cardiomyopathy.
Results suggest targeting myosin-cMyBP-C interactions could be a promising therapeutic avenue for hypertrophic cardiomyopathy patients.

Cite This Study

Rzewnicki et al. (2025) studied this question.

synapsesocial.com/papers/68e80eb363e2e2f707877deb https://doi.org/10.1161/res.137.suppl_1.wed126

View Full Paper

Ask AI

Bookmark

Implication

Research uncovers how the myosin S2 region mutation alters cMyBP-C interactions, implying potential therapeutic targets in hypertrophic cardiomyopathy.

Abstract Wed126: Myosin S2 and cMyBP-C Interactions in Cardiac Contractility and Hypertrophic Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract Wed126: Myosin S2 and cMyBP-C Interactions in Cardiac Contractility and Hypertrophic Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider